🚀 VC round data is live in beta, check it out!
- Public Comps
- Genxone
Genxone Valuation Multiples
Discover revenue and EBITDA valuation multiples for Genxone and similar public comparables like Aton, Modus Therapeutics, Instituto Rosenbusch, Akari Therapeutics and more.
Genxone Overview
About Genxone
Genxone SA is a biotechnology company that applies nanopore sequencing technology (third-generation of NGS) to many areas of science and business, including genetic diagnostics and the food industry. It specializes in developing new products and solutions based on the latest technologies of nucleic acid sequencing. The company's services include NANOPORE SEQUENCING that includes Whole Genome Sequencing, Bespoke Analysis, Metagenome Sequencing, Bioinformatic Analysis, 16S and/or ITS Gene Sequencing, and RNA Sequencing; and DIAGNOSTIC TESTS that includes Gastrointestinal Infections Panel, Respiratory Infections Panel, Urogenital Infection Panel, and Nervous System Infection Panel.
Founded
2016
HQ

Employees
N/A
Website
Sectors
Financials (FY)
EV
$5M
Genxone Financials
Genxone reported last fiscal year revenue of $653K and negative EBITDA of ($308K).
In the same fiscal year, Genxone generated $359K in gross profit, ($308K) in EBITDA losses, and had net loss of ($597K).
Genxone P&L
In the most recent fiscal year, Genxone reported revenue of $653K and EBITDA of ($308K).
Genxone expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $653K | XXX | XXX | XXX |
| Gross Profit | — | XXX | $359K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 55% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($308K) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (47%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (103%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($597K) | XXX | XXX | XXX |
| Net Margin | — | XXX | (92%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Genxone Stock Performance
Genxone has current market cap of $6M, and enterprise value of $5M.
Market Cap Evolution
Genxone's stock price is $1.75.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5M | $6M | 0.1% | XXX | XXX | XXX | $-0.18 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGenxone Valuation Multiples
Genxone trades at 7.4x EV/Revenue multiple, and (15.7x) EV/EBITDA.
Genxone Financial Valuation Multiples
As of April 19, 2026, Genxone has market cap of $6M and EV of $5M.
Equity research analysts estimate Genxone's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Genxone has a P/E ratio of (9.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6M | XXX | $6M | XXX | XXX | XXX |
| EV (current) | $5M | XXX | $5M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 7.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (15.7x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (7.2x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 13.5x | XXX | XXX | XXX |
| P/E | — | XXX | (9.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (7.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Genxone Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Genxone Margins & Growth Rates
Genxone's revenue in the last fiscal year grew by 31%.
Genxone Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 31% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (47%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (57%) | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 158% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Genxone Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Genxone | XXX | XXX | XXX | XXX | XXX | XXX |
| Aton | XXX | XXX | XXX | XXX | XXX | XXX |
| Modus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Instituto Rosenbusch | XXX | XXX | XXX | XXX | XXX | XXX |
| Akari Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Institute of Biomedical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genxone M&A Activity
Genxone acquired XXX companies to date.
Last acquisition by Genxone was on XXXXXXXX, XXXXX. Genxone acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Genxone
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGenxone Investment Activity
Genxone invested in XXX companies to date.
Genxone made its latest investment on XXXXXXXX, XXXXX. Genxone invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Genxone
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Genxone
| When was Genxone founded? | Genxone was founded in 2016. |
| Where is Genxone headquartered? | Genxone is headquartered in Poland. |
| Is Genxone publicly listed? | Yes, Genxone is a public company listed on Warsaw Stock Exchange. |
| What is the stock symbol of Genxone? | Genxone trades under GX1 ticker. |
| When did Genxone go public? | Genxone went public in 2020. |
| Who are competitors of Genxone? | Genxone main competitors are Aton, Modus Therapeutics, Instituto Rosenbusch, Akari Therapeutics. |
| What is the current market cap of Genxone? | Genxone's current market cap is $6M. |
| What is the current revenue of Genxone? | Genxone's last fiscal year revenue is $653K. |
| What is the current EV/Revenue multiple of Genxone? | Current revenue multiple of Genxone is 7.4x. |
| Is Genxone profitable? | No, Genxone is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.